{"id":"https://openalex.org/W4244039656","doi":"https://doi.org/10.1182/blood.v122.21.3193.3193","title":"Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment Of Patients (Pts) With Multiple Myeloma Who Are Not Candidates For High Dose Chemotherapy","display_name":"Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment Of Patients (Pts) With Multiple Myeloma Who Are Not Candidates For High Dose Chemotherapy","publication_year":2013,"publication_date":"2013-11-15","ids":{"openalex":"https://openalex.org/W4244039656","doi":"https://doi.org/10.1182/blood.v122.21.3193.3193"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v122.21.3193.3193","doi":"https://doi.org/10.1182/blood.v122.21.3193.3193","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.3193.3193","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050961257","display_name":"Jes\u00fas G. Berdeja","orcid":"https://orcid.org/0000-0003-4362-0376","observed_orcids":["https://orcid.org/0000-0003-4362-0376"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jesus Berdeja","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, TN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, TN, USA,","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049400849","display_name":"Michael Robert Savona","orcid":"https://orcid.org/0000-0003-3763-5504","observed_orcids":["https://orcid.org/0000-0003-3763-5504"]},"institutions":[{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Savona","raw_affiliation_strings":["Tennessee Oncology PLLC, Nashville, TN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tennessee Oncology PLLC, Nashville, TN, USA,","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052348131","display_name":"Luis Chu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Luis Chu","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, TN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, TN, USA,","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044422916","display_name":"James H. Essell","orcid":"https://orcid.org/0000-0002-9173-0310","observed_orcids":["https://orcid.org/0000-0002-9173-0310"]},"institutions":[{"id":"https://openalex.org/I4210153992","display_name":"Oncology Hematology Care","ror":"https://ror.org/04gqr8882","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210153992"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"James Essell","raw_affiliation_strings":["Oncology Hematology Care, Inc., Cincinnati, OH, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Hematology Care, Inc., Cincinnati, OH, USA,","institution_ids":["https://openalex.org/I4210153992"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Patrick Murphy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Patrick Murphy","raw_affiliation_strings":["Tennessee Oncology PLLC, Nashville, TN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tennessee Oncology PLLC, Nashville, TN, USA,","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037195922","display_name":"Todd Michael Bauer","orcid":"https://orcid.org/0000-0002-3078-5043","observed_orcids":["https://orcid.org/0000-0002-3078-5043"]},"institutions":[{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Todd Bauer","raw_affiliation_strings":["Tennessee Oncology PLLC, Nashville, TN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tennessee Oncology PLLC, Nashville, TN, USA,","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057381252","display_name":"Eric L. Raefsky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric Raefsky","raw_affiliation_strings":["Tennessee Oncology PLLC, Nashville, TN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tennessee Oncology PLLC, Nashville, TN, USA,","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112233517","display_name":"Ralph Vincent Boccia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210129209","display_name":"Center for Cancers and Blood Disorders","ror":"https://ror.org/03jh7ct92","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210129209"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ralph V. Boccia","raw_affiliation_strings":["Center for Cancer and Blood Disorders, Bethesda, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Cancer and Blood Disorders, Bethesda, MD, USA","institution_ids":["https://openalex.org/I4210129209"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000959540","display_name":"Ian W. Flinn","orcid":"https://orcid.org/0000-0001-6724-290X","observed_orcids":["https://orcid.org/0000-0001-6724-290X"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ian Flinn","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, TN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, TN, USA,","institution_ids":["https://openalex.org/I4210100810"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5037195922","https://openalex.org/A5044422916"],"corresponding_institution_ids":["https://openalex.org/I4210135086","https://openalex.org/I4210153992"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":1.425,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":{"value":0.83931744,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"122","issue":"21","first_page":"3193","last_page":"3193"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.984000027179718},{"id":"https://openalex.org/keywords/bendamustine","display_name":"bendamustine","score":0.9700000286102295},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":1.0},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":1.0},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8579999804496765},{"id":"https://openalex.org/keywords/newly-diagnosed-multiple-myeloma","display_name":"newly diagnosed multiple myeloma","score":0.8759999871253967},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.6779999732971191},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.5989999771118164},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6700000166893005},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.49300000071525574},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.5429999828338623},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.7300000190734863},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.414000004529953},{"id":"https://openalex.org/keywords/alkylating-agents","display_name":"alkylating agents","score":0.5239999890327454}],"concepts":[{"id":"https://openalex.org/C2781442060","wikidata":"https://www.wikidata.org/wiki/Q425745","display_name":"Bendamustine","level":4,"score":0.943501889705658},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.7944378852844238},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7538551092147827},{"id":"https://openalex.org/C2778684742","wikidata":"https://www.wikidata.org/wiki/Q2298283","display_name":"Melphalan","level":3,"score":0.5572168827056885},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.555576503276825},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.5469425916671753},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.5394576191902161},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4771120846271515},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.4605187177658081},{"id":"https://openalex.org/C2778670039","wikidata":"https://www.wikidata.org/wiki/Q414004","display_name":"Nitrogen mustard","level":4,"score":0.451094388961792},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.42916980385780334},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.41449955105781555},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.35919028520584106},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.3548635244369507},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.32812121510505676},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2095031440258026},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.12263765931129456}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v122.21.3193.3193","doi":"https://doi.org/10.1182/blood.v122.21.3193.3193","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.3193.3193","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2557622287","https://openalex.org/W2238052692","https://openalex.org/W2564956463","https://openalex.org/W2587731384","https://openalex.org/W2981076752","https://openalex.org/W2578297775","https://openalex.org/W2471307268","https://openalex.org/W2554370865","https://openalex.org/W2552255570","https://openalex.org/W4379339731"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Despite":[2],"significant":[3],"advances,":[4],"multiple":[5],"myeloma":[6],"is":[7,71,581,588,599,623,641],"an":[8,14],"incurable":[9],"plasma":[10],"cell":[11],"disorder":[12],"with":[13,76,123,137,154,198,608],"eventual":[15],"fatal":[16],"outcome.":[17],"In":[18,104],"newly":[19,138],"diagnosed":[20,139],"MM,":[21],"combinations":[22,89],"of":[23,40,49,93,109,131,279,367,392,405,435,444,457,471,488,505,516,575,594,612,617,649,654],"bortezomib,":[24],"steroids":[25],"and":[26,32,42,86,112,149,159,188,261,318,355,390,410,491,534,553,568,584,597,601],"alkylating":[27,74],"agents,":[28],"such":[29],"as":[30,46,82,117,339],"melphalan":[31],"prednisone,":[33],"have":[34,43,371],"achieved":[35],"response":[36,334],"rates":[37],"in":[38,51,64,87,398,433,455,469,503,603,651],"excess":[39],"70%":[41],"been":[44,372],"established":[45],"a":[47,72,77,83,118,234,277,572,609],"standard":[48,151],"care":[50],"pts":[52,65,122,370,393,406,417,472,518,541,559,613,627],"who":[53,142],"are":[54,61],"ineligible":[55],"for":[56,90,121,146,276,307,521],"high":[57],"dose":[58],"chemotherapy.":[59],"Outcomes":[60],"more":[62],"attenuated":[63],">":[66,395,560],"75":[67,388,396,618],"yrs":[68],"old.":[69],"Bendamustine":[70,650],"bi-functional":[73],"agent":[75,85],"purine-like":[78],"benzimidazole":[79],"ring":[80],"effective":[81],"single":[84],"various":[88],"the":[91,107,128,206,236,242,322,329,348,362,376,381,399,423,477,506,510,538,543,547,557,562,578,585,615,652],"treatment":[92,166,210,237,493,512,545,632],"relapsed/refractory":[94],"MM":[95,141],"(Poenisch":[96],"et":[97,101],"al,":[98,102],"2007,":[99],"Fenk":[100],"2007).":[103],"this":[105,132,225,604],"study,":[106],"combination":[108,226,593],"bendamustine,":[110,595],"bortezomib":[111,178,252,300,596],"dexamethasone":[113,189,262,598],"(BBD)":[114],"was":[115,239,315,337,387,446,466,481,501,525,549,564],"evaluated":[116],"first-line":[119],"therapy":[120],"MM.":[124],"Here":[125],"we":[126],"present":[127],"updated":[129],"results":[130],"ongoing":[133],"trial.":[134],"Methods":[135],"Pts":[136,204,291],"active":[140],"were":[143,162,326,345,359,394,407,412,431,453,519],"not":[144],"candidates":[145],"high-dose":[147],"chemotherapy":[148],"met":[150],"eligibility":[152],"criteria":[153],"regards":[155],"to":[156,208,212,227,241,298,628,630,637],"renal,":[157],"hepatic":[158],"hematologic":[160,429,442],"function":[161],"enrolled.":[163],"The":[164,332,384,459,523,592,620],"original":[165,377,478,511],"schema":[167,238,622],"consisted":[168],"of:":[169],"bendamustine":[170,244],"80":[171,245],"mg/m2":[172,180,246,254,302],"IV":[173,181,247,255],"on":[174,182,192,248,256,265,297,321,375,380,419,422,476,542],"days":[175,183,193,249,257,266,275],"1,":[176,184,194,250,258,267],"4;":[177],"1.3":[179,253,301],"4,":[185],"8,":[186,259,269],"11;":[187],"40":[190,517],"mg":[191,264],"2,":[195,268],"3,":[196],"4":[197,441,485],"cycles":[199,214,217,281,284],"repeating":[200],"every":[201,273,304],"28":[202,274],"days.":[203],"had":[205],"option":[207],"continue":[209],"up":[211],"8":[213,280],"or":[215,282,311],"2":[216,283,305,308],"beyond":[218,285],"confirmed":[219],"CR.":[220],"An":[221],"interim":[222],"analysis":[223],"found":[224],"be":[228],"efficacious":[229,602],"but":[230,474],"relatively":[231],"toxic.":[232],"As":[233,366],"result,":[235],"amended":[240],"following:":[243],"2;":[251],"15;":[260],"20":[263],"9,":[270],"15,":[271],"16":[272],"total":[278,515],"documented":[286],"CR,":[287],"whichever":[288],"occurred":[289],"first.":[290],"achieving":[292],"at":[293],"least":[294],"SD":[295,533],"continued":[296],"maintenance":[299,631],"IV/SQ":[303],"weeks":[306],"years.":[309,619],"Acyclovir":[310],"equivalent":[312],"viral":[313],"prophylaxis":[314],"originally":[316],"recommended":[317],"became":[319],"required":[320],"modified":[323,382,400,424,544,621],"schema.":[324,425,513],"Responses":[325],"assessed":[327,346],"using":[328,347,361],"IMWG":[330],"criteria.":[331],"overall":[333],"rate":[335],"(ORR)":[336],"defined":[338],"\u2265":[340],"PR.":[341],"Adverse":[342],"Events":[343],"(AEs)":[344],"CTCAE":[349],"Version":[350],"4.0.":[351],"Overall":[352],"survival":[353,357],"(OS)":[354],"progression-free":[356],"(PFS)":[358],"calculated":[360],"Kaplan-Meier":[363],"method.":[364],"Results":[365],"5/31/2013,":[368],"43":[369],"enrolled":[373],"(18":[374],"schema,":[378,546],"25":[379],"schema).":[383,401,479],"median":[385,573],"age":[386,616],"(45-89)":[389],"39%":[391],"(48%":[397],"Forty":[402],"two":[403],"percent":[404],"ISS":[408,413],"II":[409],"32%":[411],"III.":[414],"Fifteen":[415],"(35%)":[416],"remain":[418],"treatment,":[420],"all":[421,508],"Treatment-related":[426,448],"Grade":[427,440,449,463,484],"3":[428,450,464],"AEs":[430,452],"seen":[432,454,468,502],"30%":[434],"pts.":[436,458],"Only":[437],"1":[438,475,482,492],"treatment-related":[439,483],"AE":[443,465,487],"neutropenia":[445],"observed.":[447],"non-hematologic":[451,462,486],"21%":[456],"most":[460],"common":[461],"neuropathy,":[467],"12%":[470],"(all":[473],"There":[480],"atrial":[489],"fibrillation":[490],"related":[494],"death":[495],"(congestive":[496],"heart":[497],"failure).":[498],"Herpes":[499],"Zoster":[500],"19%":[504],"pts,":[507],"from":[509],"A":[514],"evaluable":[520,540],"response.":[522],"ORR":[524,548,563],"83%":[526,550,589],"(55%":[527],"\u2265VGPR,":[528],"28%":[529],"PR)":[530],"plus":[531],"17%":[532],"0":[535],"PD.":[536],"Of":[537],"23":[539],"(52%":[551],"\u2265VGPR":[552,567],"31%":[554],"PR).":[555,570],"For":[556],"15":[558],"75,":[561],"93%":[565],"(60%":[566],"33%":[569],"At":[571],"FU":[574],"13.1":[576],"months,":[577],"1-year":[579,586],"PFS":[580],"79%":[582],"(0.53-0.92)":[583],"OS":[587],"(0.54-0.95).":[590],"Conclusion":[591],"feasible":[600],"elderly":[605],"pt":[606],"population":[607],"large":[610],"number":[611],"over":[614],"better":[624],"tolerated":[625],"allowing":[626],"proceed":[629],"which":[633],"may":[634],"eventually":[635],"translate":[636],"improved":[638],"results.":[639],"Enrollment":[640],"ongoing.":[642],"Disclosures:":[643],"Off":[644],"Label":[645],"Use:":[646],"Off-label":[647],"use":[648],"Treatment":[653],"Multiple":[655],"Myeloma.":[656],"Chu:Teva:":[657],"Research":[658,661,664,667,670,673],"Funding;":[659,665,671],"Millennium:":[660,666,672],"Funding.":[662,668,674],"Boccia:Teva:":[663],"Flinn:Teva:":[669]},"counts_by_year":[{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2022-05-12T00:00:00"}